7th Cancer Scientific Forum of the Cancéropôle Lyon Auvergne Rhône-Alpes

The Innovative Approaches in Anti-Cancer Monoclonal Antibodies meeting, held on March 20, 2012 in Lyon, was organized by Cancéropôle Lyon Auvergne-Rhône-Alps in partnership with the French competitiveness cluster Lyonbiopôle. CLARA is one of the seven cancer research clusters within France in charge of facilitating Translational Oncology Research by taking into account the objectives of the French National Cancer Plans I and II and, in coordination with the French National Cancer Institute and local authorities (mainly Grand Lyon, Rhône County and Rhône-Alpes Region), to perform economic development of research findings. The contribution of lectures by outstanding speakers as described in this report, the organization of two-round tables: “Antibody treatment in cancer: Unmet needs in solid tumors and hematological malignancies,” and “From chimeric to more than human antibodies,” together with face-to-face meetings, was shared by over 230 participants. The lectures provided an overview of the commercial pipeline of monoclonal antibody (mAb) therapeutics for cancer; discussion of the distinction between biosimilar, biobetter and next generation therapeutic antibodies for cancer; updates on obinutuzumab and the use of mAbs in lymphoma; and discussion of antibody-drug conjugates.

[1]  G. Salles,et al.  Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. , 2012, Blood.

[2]  R. Gascoyne,et al.  A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. , 2012, Blood.

[3]  Alain Van Dorsselaer,et al.  Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. , 2012, Analytical chemistry.

[4]  Janice M. Reichert,et al.  Marketed therapeutic antibodies compendium , 2012, mAbs.

[5]  H. Pelicano,et al.  Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. , 2012, Blood.

[6]  R. Ueda,et al.  Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Reichert.  Which are the antibodies to watch in 2012? , 2012, mAbs.

[8]  Scott C. Williams,et al.  Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’ , 2011, The Yale journal of biology and medicine.

[9]  C. Klein,et al.  CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. , 2011, Blood.

[10]  Herren Wu,et al.  A glycoengineered anti‐CD19 antibody with potent antibody‐dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo , 2011, British journal of haematology.

[11]  M. Sliwkowski,et al.  Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer , 2011, Clinical Cancer Research.

[12]  A. Younes,et al.  Brentuximab Vedotin (SGN-35) , 2011, Clinical Cancer Research.

[13]  A. Ricart.  Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin , 2011, Clinical Cancer Research.

[14]  I. Pastan,et al.  Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox , 2011, Clinical Cancer Research.

[15]  B. Teicher,et al.  Antibody Conjugate Therapeutics: Challenges and Potential , 2011, Clinical Cancer Research.

[16]  D. Neri,et al.  Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends , 2011, Clinical Cancer Research.

[17]  R. Lutz,et al.  SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies , 2011, Clinical Cancer Research.

[18]  G. Nightingale.  Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Treatment of Refractory Chronic Lymphocytic Leukemia , 2011, The Annals of pharmacotherapy.

[19]  Janice M Reichert,et al.  Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies , 2011, mAbs.

[20]  M. Czuczman,et al.  Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. , 2011, Future oncology.

[21]  Armin Ruf,et al.  Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose , 2011, Proceedings of the National Academy of Sciences.

[22]  C. Klein,et al.  Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. , 2011, Blood.

[23]  B. Teicher,et al.  Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling. , 2011, International journal of oncology.

[24]  H. Kluin-Nelemans,et al.  Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  A. Beck,et al.  World Antibody Drug Conjugate Summit Europe , 2011, mAbs.

[26]  Guy Georges,et al.  Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies , 2011, Proceedings of the National Academy of Sciences.

[27]  T. Illidge,et al.  Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. , 2011, Blood.

[28]  R. Elstrom,et al.  Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma , 2011, Haematologica.

[29]  A. Beck.  Biosimilar, biobetter and next generation therapeutic antibodies , 2011, mAbs.

[30]  C. Klein,et al.  Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells , 2011, British journal of haematology.

[31]  Andrew Lister,et al.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.

[32]  M. Hallek,et al.  Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies , 2011, Clinical Cancer Research.

[33]  J. Reichert.  Antibody-based therapeutics to watch in 2011 , 2011, mAbs.

[34]  C. Klein,et al.  Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101 , 2011, Molecular Cancer Therapeutics.

[35]  Janice M Reichert,et al.  Metrics for antibody therapeutics development , 2010, mAbs.

[36]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[37]  Christian Bailly,et al.  The next generation of antibody-drug conjugates comes of age. , 2010, Discovery medicine.

[38]  F. d'Amore,et al.  Phase II trial of zanolimumab (HuMax‐CD4) in relapsed or refractory non‐cutaneous peripheral T cell lymphoma , 2010, British journal of haematology.

[39]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[40]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[41]  Teicher Ba.  Antibody-drug conjugate targets. , 2009 .

[42]  Nancy Whiting,et al.  Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Reichert,et al.  European Medicines Agency workshop on biosimilar monoclonal antibodies , 2009, mAbs.

[44]  P. Tak,et al.  Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis , 2009, Annals of the rheumatic diseases.

[45]  Andreas Radbruch,et al.  B-cell-directed therapies for autoimmune disease , 2009, Nature Reviews Rheumatology.

[46]  J. Leonard,et al.  A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma , 2009, British journal of haematology.

[47]  T. Waldmann,et al.  EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies , 2009, Clinical Cancer Research.

[48]  J. Rossi,et al.  Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.

[49]  B. Teicher,et al.  Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma , 2008, Clinical Cancer Research.

[50]  S. Ansell,et al.  Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  T. Illidge,et al.  Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. , 2007, Blood.

[52]  J. Leonard,et al.  Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies , 2007, Oncogene.

[53]  G. Schwarzer,et al.  Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.

[54]  P. Parren,et al.  The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 , 2006, The Journal of Immunology.

[55]  C. Dearden.  The role of alemtuzumab in the management of T-cell malignancies. , 2006, Seminars in oncology.

[56]  M. Erlanson,et al.  A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. , 2004, Blood.

[57]  M. Baccarani,et al.  Clinical Observations, Interventions, and Therapeutic Trials , 2000 .

[58]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[59]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Camellia W. Adams,et al.  An efficient route to human bispecific IgG , 1998, Nature Biotechnology.

[61]  R. Lutz,et al.  SAR 3419 : An Anti-CD 19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies , 2011 .

[62]  B. Teicher.  Antibody-drug conjugate targets. , 2009, Current cancer drug targets.

[63]  R. Fanin,et al.  B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. , 2002, Haematologica.

[64]  D. Czerwinski,et al.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. , 1994, Blood.